Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANGel-Dox01,02
- Development stage
- Preclinical
- Lead developer
- OncoLab
- Modality
- Small Molecules, Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
ANGel-Dox01,02 is a next-generation preclinical therapeutic candidate being developed by OncoLab for the treatment of triple-negative breast cancer (TNBC). It is built on OncoLab's proprietary ANGel platform, which is a hydrogel microparticle-based precision formulation and delivery system. ANGel-Dox01,02 is designed for peritumoral or perilesional subcutaneous administration to provide localized and sustained co-delivery of a multi-antibody configuration and a small-molecule payload (potentially doxorubicin, as suggested by the 'Dox' designation) without requiring molecular redesign. This approach aims to achieve bispecific-like multi-mechanism targeting and antibody-drug conjugate (ADC)-like payload delivery directly at the tumor site while minimizing systemic exposure.
- Other names
- ANGel-Dox01/02
Beyond the preview
Go deeper on ANGel-Dox01,02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANGel-Dox01,02.